
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice</strong></summary>
            <div>
                <ul><li>- World J Gastroenterol. Aug 7, 2025; 31(29): 107745</li><li>- DOI: 10.3748/wjg.v31.i29.107745</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- In the VARSITY study, what were the specific clinical remission rates at week 52 for vedolizumab vs. adalimumab in UC?</li><li>- In the EFFICACI trial for UC patients who failed a first SC anti-TNF, what was the steroid-free clinical remission rate at week 14 for vedolizumab?</li><li>- What is the recommended folic acid supplementation dose for pregnant individuals on sulfasalazine?</li><li>- In the SEQUENCE study comparing risankizumab and ustekinumab in CD, what was the superior endoscopic remission rate for risankizumab at week 48?</li><li>- In the TACOS study for ASUC, what was the response rate in the group receiving hydrocortisone plus tofacitinib?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction & Core Concepts</strong></summary>
            <div>
                <ul><li>- <b>Inflammatory Bowel Disease (IBD)</b>, including Crohn's Disease (CD) and Ulcerative Colitis (UC), are incurable immune-mediated disorders requiring advanced therapies.</li><li>- The therapeutic arsenal has expanded beyond <b>anti-TNF-α</b> agents to include multiple new classes.</li></ul>
                
        <details>
            <summary><strong>Key Terminology</strong></summary>
            <div>
                <ul><li>- <b><u>Positioning</u></b>: Selecting the optimal <u>first-line</u> advanced therapy based on patient profile, disease activity, and drug attributes.</li><li>- <b><u>Sequencing</u></b>: Strategic selection of <u>subsequent</u> therapies after the failure of the initial treatment (due to non-response, loss of response, or adverse events).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Expanded Therapeutic Armamentarium</strong></summary>
            <div>
                <ul><li>- <b>Anti-integrin agents</b> (e.g., vedolizumab)</li><li>- <b>Interleukin (IL) inhibitors</b> (IL-12/23 and IL-23p19)</li><li>- <b>Janus kinase (JAK) inhibitors</b> (e.g., tofacitinib, upadacitinib)</li><li>- <b>Sphingosine 1-phosphate (S1P) receptor modulators</b> (e.g., ozanimod, etrasimod)</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>General Principles of Therapy Selection</strong></summary>
            <div>
                <ul><li>- Decisions are guided by evidence (RCTs, NMAs, RWE), clinical expertise, and shared decision-making.</li><li>- Early initiation of biologics in CD, ideally within <q>the first 12 months</q> of diagnosis, improves outcomes and enhances transmural healing rates.</li></ul>
                
        <details>
            <summary><strong>Fundamental Principles (Table 2)</strong></summary>
            <div>
                <ul><li>- <b>Start early</b>: Initiate effective drugs as soon as possible.</li><li>- <b>First is best</b>: The first advanced therapy chosen is often the most effective, especially in CD.</li><li>- <b>Avoid steroid cycles</b>: The need for steroids signals the necessity for steroid-sparing therapies.</li><li>- <b>Think ahead</b>: Always consider which agent could be an effective second-line treatment.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Factors Influencing Choice</strong></summary>
            <div>
                <ul><li>- <b>Patient-specific</b>: Age, frailty, comorbidities, extraintestinal manifestations (EIMs), preferences (oral vs. IV/SC).</li><li>- <b>Disease-specific</b>: Severity, phenotype (e.g., fistulizing CD), inflammatory load, hypoalbuminemia.</li><li>- <b>Drug-specific</b>: Speed of onset, efficacy, safety profile, route of administration, cost, and access.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Timeframe for Assessing Effectiveness (Table 1)</strong></summary>
            <div>
                <ul><li>- A structured approach is needed to avoid premature discontinuation or delays in switching ineffective therapies.</li><li>- Most effective therapies show response within <q>2-4 weeks</q>, but delayed responses can occur.</li></ul>
                
        <details>
            <summary><strong>Specific Regimens & Timeframes</strong></summary>
            <div>
                <ul><li>- <b>Anti-TNF</b>: Assess after <q>2-3 loading doses</q> and the first maintenance dose.</li><li>- <b>Vedolizumab (Anti-integrin)</b>: Assess after <q>3 loading doses</q> and 1-3 maintenance doses.</li><li>- <b>JAK Inhibitors</b>:</li><li>- - Tofacitinib: <q>10 mg PO BID for 8-16 weeks</q>.</li><li>- - Upadacitinib (UC): <q>45 mg PO QD for 8-16 weeks</q>.</li><li>- - Upadacitinib (CD): <q>45 mg PO QD for 12 weeks</q>.</li><li>- <b>S1P Modulators</b>:</li><li>- - Ozanimod: <q>0.92 mg/day for 10 weeks</q>.</li><li>- - Etrasimod: <q>2 mg PO QD for 12 weeks</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Positioning & Sequencing in <b>Ulcerative Colitis (UC)</b></strong></summary>
            <div>
                <ul><li>- The initial therapeutic choice can impact the effectiveness of future treatments.</li><li>- Achieving steroid-free remission and mucosal healing remains challenging, especially in therapy-experienced patients.</li></ul>
                
        <details>
            <summary><strong>First-Line Therapy (Biologic-Naive)</strong></summary>
            <div>
                <ul><li>- The <b>VARSITY</b> study was the first head-to-head trial comparing two biologic classes in UC.</li></ul>
                
        <details>
            <summary><strong><b>VARSITY Trial</b>: Vedolizumab vs. Adalimumab</strong></summary>
            <div>
                <ul><li>- At week 52, <b>vedolizumab</b> was superior to adalimumab for:</li><li>- - <u>Clinical Remission</u>: <q><b>31.3%</b></q> vs <q>22.5%</q> (p=0.0061).</li><li>- - <u>Mucosal Healing</u>: <q><b>39.7%</b></q> vs <q>27.7%</q> (p=0.0005).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Network Meta-Analysis (NMA) Insights</strong></summary>
            <div>
                <ul><li>- <b>Upadacitinib</b> is ranked as the <u>most effective</u> therapy for both biologic-naive and experienced populations.</li><li>- When JAK inhibitors are excluded, <b>infliximab, ozanimod, risankizumab, and guselkumab</b> show greater benefit than adalimumab and mirikizumab.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Speed of Onset</strong></summary>
            <div>
                <ul><li>- Rapid onset is crucial for patients needing urgent symptom control.</li><li>- <b>JAK inhibitors</b>: Upadacitinib provides relief as early as <q>day 1</q>; Tofacitinib shows significant symptom reduction by <q>day 3</q>.</li><li>- <b>Infliximab (IFX)</b>: Demonstrates early reductions in stool frequency and rectal bleeding.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Patient Preference</strong></summary>
            <div>
                <ul><li>- A nationwide study found <b>oral therapy</b> was most preferred (Acceptability Score = <q>8.68</q>), followed by SC injections and IV infusions.</li><li>- SC therapies with extended intervals (<u>≥ 8 weeks</u>) were highly acceptable.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management After Biologic Failure</strong></summary>
            <div>
                <ul><li>- No direct head-to-head trials exist specifically for anti-TNF refractory patients, so decisions rely on RWE and NMAs.</li></ul>
                
        <details>
            <summary><strong>Real-World Evidence (RWE)</strong></summary>
            <div>
                <ul><li>- <b>Tofacitinib vs. Ustekinumab</b>: Comparable corticosteroid-free remission at week 16 (<q>37.8%</q> vs <q>35.6%</q>).</li><li>- <b>Tofacitinib vs. Vedolizumab</b>: Tofacitinib showed significantly higher remission rates at week 52 (<q>47.1%</q> vs <q>23.5%</q>).</li><li>- <b>EFFICACI Trial</b> (post-SC anti-TNF failure): <b>Vedolizumab</b> was superior to infliximab for steroid-free clinical remission at week 14 (<q><b>34.6%</b></q> vs <q>19.2%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Meta-Analysis Findings</strong></summary>
            <div>
                <ul><li>- <b>Lymphocyte trafficking inhibitors</b> (anti-integrins, S1P modulators) are <u>more effective</u> in TNF-naive vs. TNF-exposed patients.</li><li>- <b>JAK inhibitors</b> may be <u>less effective</u> in TNF-naive than in TNF-exposed patients.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Multirefractory UC</strong></summary>
            <div>
                <ul><li>- This population fails multiple lines of therapy (anti-TNF, integrin inhibitors, JAK inhibitors, etc.).</li><li>- Newer agents have been studied in more heavily pre-treated populations.</li></ul>
                
        <details>
            <summary><strong>IL-23p19 Inhibitors</strong></summary>
            <div>
                <ul><li>- <b>Mirikizumab (LUCENT trials)</b>: Showed efficacy in patients where <q>40%</q> had failed prior biologics.</li><li>- <b>Risankizumab</b>: Showed meaningful remission in a population where <q>~50%</q> had failed prior advanced therapies.</li><li>- <b>Guselkumab (QUASAR program)</b>: Effective in patients with multiple prior biologic failures, including anti-TNF, vedolizumab, and tofacitinib.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>S1P Receptor Modulators</strong></summary>
            <div>
                <ul><li>- <b>Etrasimod (ELEVATE trials)</b>: Effective in biologic-experienced patients, with higher remission rates in those with only <q>one</q> prior biologic/JAK inhibitor failure vs. multiple failures.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Acute Severe UC (ASUC)</strong></summary>
            <div>
                <ul><li>- Standard rescue therapy for steroid-refractory ASUC is <b>infliximab</b> or <b>cyclosporine</b>.</li><li>- <b>JAK inhibitors</b> are promising options due to rapid onset, especially after IFX failure.</li></ul>
                
        <details>
            <summary><strong>Tofacitinib in ASUC</strong></summary>
            <div>
                <ul><li>- Systematic review: Associated with a 90-day colectomy-free survival rate of <q><b>86%</b></q> in refractory patients.</li><li>- <b>TACOS study (RCT)</b>: Combining hydrocortisone with tofacitinib significantly increased response rates (<q><b>83.01%</b></q> vs <q>58.82%</q> with placebo).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Upadacitinib in ASUC</strong></summary>
            <div>
                <ul><li>- RWE suggests efficacy and safety comparable to infliximab, with no significant difference in colectomy rates.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Positioning & Sequencing in <b>Crohn's Disease (CD)</b></strong></summary>
            <div>
                <ul><li>- Management goals include rapid remission, maintaining steroid-free remission, and targeting deeper outcomes like endoscopic and transmural healing.</li></ul>
                
        <details>
            <summary><strong>Key Management Strategies</strong></summary>
            <div>
                <ul><li>- <b>Early Intervention</b>: A 'top-down' approach (early combined immunosuppression) is linked to better long-term outcomes.</li><li>- <b>PROFILE study</b>: Top-down approach resulted in significantly higher sustained steroid- and surgery-free remission (<q><b>79%</b></q> vs <q>15%</q> for accelerated step-up).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Comparative Studies & Meta-Analyses</strong></summary>
            <div>
                <ul><li>- Head-to-head trials and NMAs are crucial for guiding therapy choices.</li></ul>
                
        <details>
            <summary><strong>Head-to-Head Trials</strong></summary>
            <div>
                <ul><li>- <b>SONIC study</b>: Combination therapy with <b>infliximab + azathioprine</b> was superior to either monotherapy in biologic-naive patients.</li><li>- <b>SEAVUE trial</b>: <b>Ustekinumab vs. Adalimumab</b> (biologic-naive) showed similar clinical remission rates at week 52 (<q>64.9%</q> vs <q>61.0%</q>).</li><li>- <b>SEQUENCE study</b>: <b>Risankizumab vs. Ustekinumab</b> (anti-TNF failure) showed risankizumab was <u>non-inferior</u> for clinical remission at week 24 and <u>superior</u> for endoscopic remission at week 48 (<q><b>31.8%</b></q> vs <q>16.2%</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Network Meta-Analysis (NMA) Insights</strong></summary>
            <div>
                <ul><li>- <b>Biologic-Naive</b>: <b>Infliximab</b> and <b>adalimumab</b> ranked highest for inducing clinical remission.</li><li>- <b>Biologic-Exposed</b>: <b>Risankizumab</b> was the most effective agent.</li><li>- <b>Maintenance</b>: <b>Upadacitinib 30 mg</b> ranked highest.</li><li>- <b>Fistulizing CD</b>: <b>Infliximab</b> remains the preferred first-line therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Real-World Evidence (RWE)</strong></summary>
            <div>
                <ul><li>- <b>ROTARY study</b>: First-line treatment with <b>infliximab</b> or <b>vedolizumab</b> was associated with significantly lower rates of switching or discontinuation compared to adalimumab.</li><li>- Vedolizumab was found to be more effective when used as a <u>first-line</u> agent.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Postoperative Recurrence</strong></summary>
            <div>
                <ul><li>- Prophylactic therapy is crucial for high-risk patients (e.g., smokers, penetrating disease, prior resection).</li><li>- Endoscopic recurrence (Rutgeerts score <q>≥ i2</q>) within 6-12 months predicts clinical relapse.</li></ul>
                
        <details>
            <summary><strong>REPREVIO Trial</strong></summary>
            <div>
                <ul><li>- <b>Vedolizumab</b> significantly reduced severe endoscopic recurrence at week 26 compared to placebo (<q>23.3%</q> vs <q>62.2%</q>).</li><li>- This suggests VDZ is a viable option for preventing postoperative recurrence.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment of Recurrence</strong></summary>
            <div>
                <ul><li>- If recurrence occurs despite prophylaxis, first step is to optimize existing therapy (e.g., dose escalate).</li><li>- For those without prophylaxis, <b>anti-TNF agents</b> are a common first-line choice. <b>Ustekinumab</b> is an effective option after prior biologic failure.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Managing Secondary Loss of Response (LOR)</strong></summary>
            <div>
                <ul><li>- A personalized approach is required, ideally guided by Therapeutic Drug Monitoring (TDM).</li></ul>
                
        <details>
            <summary><strong>TDM-Guided Approach for Anti-TNF</strong></summary>
            <div>
                <ul><li>- <b>Subtherapeutic drug levels</b> (no antibodies) ---> Benefit from dose escalation.</li><li>- <b>High anti-drug antibody levels</b> ---> Switch to another anti-TNF or a different class.</li><li>- <b>Adequate drug levels</b> (pharmacodynamic failure) ---> Switch to a different class.</li><li>- <u>Do not discontinue</u> anti-TNF therapy before reaching adequate trough levels (e.g., IFX/ADA > <q>10-15 μg/mL</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>LOR to Non-Anti-TNF Therapies</strong></summary>
            <div>
                <ul><li>- The role of TDM for agents like vedolizumab and ustekinumab is less established.</li><li>- Emerging data suggests TDM can be beneficial; dose escalation of ustekinumab resulted in response/remission in <q>69%</q> of cases with LOR.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Positioning & Sequencing in Special Populations</strong></summary>
            <div>
                <ul><li>- Treatment strategies must be individualized to balance efficacy and safety in specific subgroups.</li></ul>
                
        <details>
            <summary><strong>Pregnant & Lactating Patients</strong></summary>
            <div>
                <ul><li>- Goal: Maintain remission while minimizing fetal/maternal risk.</li></ul>
                
        <details>
            <summary><strong>Safe / Generally Safe Therapies</strong></summary>
            <div>
                <ul><li>- <b>5-ASA</b>: Generally safe. Sulfasalazine requires folic acid supplementation of at least <q><b>2 mg/day</b></q>.</li><li>- <b>Thiopurines</b>: Considered safe despite FDA category D.</li><li>- <b>Anti-TNF agents</b>: Generally safe. <b>Certolizumab</b> has the lowest placental transfer.</li><li>- <b>Anti-integrin & Anti-ILs</b>: Emerging data suggest safety, especially for vedolizumab and ustekinumab.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Contraindicated Therapies</strong></summary>
            <div>
                <ul><li>- <b><u>Absolute</u> Contraindication</b>: <b>Methotrexate</b> (teratogenic); must be discontinued at least <q>3 months</q> prior to conception.</li><li>- <b><u>Relative</u> Contraindication</b>: <b>JAK inhibitors</b> (teratogenic in animal studies); must be discontinued at least <q>1 month</q> prior.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>History of Malignancy or Active Cancer</strong></summary>
            <div>
                <ul><li>- <b>Thiopurines</b>: Avoid in patients with history of EBV-related lymphoma or HPV-related carcinomas.</li><li>- <b>JAK inhibitors</b>: Malignancy risk appears concentrated in high-risk individuals (older, smokers, etc.).</li><li>- <b>Safer Options</b>: <b>Vedolizumab</b> and <b>anti-IL agents</b> have not been associated with increased cancer risk and are preferred options.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Patients with Comorbidities</strong></summary>
            <div>
                <ul><li>- <b>Cardiovascular Disease</b>: TNF inhibitors are relatively contraindicated in NYHA class <q>III-IV</q> heart failure. Vedolizumab and anti-ILs have safer profiles.</li><li>- <b>Demyelinating Diseases</b> (e.g., Multiple Sclerosis): <b>Anti-TNF agents are <u>contraindicated</u></b>. Vedolizumab and anti-ILs are preferred.</li><li>- - <b>Ozanimod (S1P modulator)</b> may be a first-line choice for UC patients with multiple sclerosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Older Individuals (≥65 years)</strong></summary>
            <div>
                <ul><li>- Increased risk of infections and adverse events.</li><li>- <b>JAK inhibitors</b>: Should be avoided in individuals <q>≥ 65 years</q> unless no other options exist, due to cardiovascular and thromboembolic risks.</li><li>- <b>Preferred First-Line</b>: <b>Vedolizumab</b> and <b>anti-IL agents</b> are considered first-line options due to their favorable safety profiles.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>IBD with Extraintestinal Manifestations (EIMs)</strong></summary>
            <div>
                <ul><li>- Management requires addressing both intestinal inflammation and specific EIMs.</li><li>- Collaboration with specialists (rheumatology, dermatology, ophthalmology) is essential.</li></ul>
                
        <details>
            <summary><strong>Therapy Effectiveness for EIMs (See Table 5)</strong></summary>
            <div>
                <ul><li>- <b>Anti-TNF agents</b>: Broadly effective for musculoskeletal, cutaneous, and ocular EIMs. Can cause paradoxical psoriasis.</li><li>- <b>Vedolizumab</b>: Effective for EIMs associated with luminal activity (e.g., erythema nodosum, type 1 peripheral arthritis) but not for independent EIMs (e.g., axial spondyloarthritis).</li><li>- <b>Anti-IL agents</b>: Particularly effective for psoriasis and psoriatic arthritis.</li><li>- <b>JAK inhibitors</b>: Effective for various arthritis types (rheumatoid, psoriatic, axial spondyloarthritis).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusion & Future Directions</strong></summary>
            <div>
                <ul><li>- IBD management is entering an era of complexity and opportunity, requiring individualized, context-sensitive strategies.</li><li>- Future research in personalized medicine (genomics, proteomics, microbiome) may allow for predictive models to guide therapy selection from the outset.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
